Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double-Blind 2-Period Multiple Dose Crossover Study to Evaluate the Efficacy and Safety of AD113 vs Atomoxetine in OSA Patients With Hypertension

NCT04905979 is registered in ClinicalTrials.gov with Apnimed as lead sponsor.

NCT NCT04905979
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04905979 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double-Blind 2-Period Multiple Dose Crossover Study to Evaluate the Efficacy and Safety of AD113 vs Atomoxetine in OSA Patients With Hypertension
Lead sponsor
Apnimed
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2021
Completion date
May 31, 2023
Enrollment
21 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, obstructive sleep apnea